重蹈覆辙:长期暴露于抗生素对创伤患者多重耐药呼吸机相关性肺炎的影响
该研究纳入10年间397例创伤后由鲍曼不动杆菌或铜绿假单胞菌所致呼吸机相关性肺炎患者,按病原体敏感性分为敏感组和多药耐药组,比较预防性和经验性抗生素使用天数、危险因素及死亡率。多药耐药组多次不恰当经验性抗生素治疗比例显著更高(81% vs 63%,p<0.001),24小时输血量(19 vs 14单位,p=0.009)和下肢简明损伤定级评分(3 vs 1,p<0.001)也显著增高。多因素logistic回归显示预防性抗生素使用天数(OR 23.1,95%CI 16.7-28,p<0.001)和多次不恰当经验性抗生素治疗(OR 18.1,95%CI 12.2-26.1,p=0.001)是多药耐药的独立预测因素。作者认为限制预防性抗生素使用天数是创伤患者发生多药耐药呼吸机相关性肺炎唯一可能可干预的危险因素。
要点
- 创伤后呼吸机相关性肺炎患者中,多药耐药组多次不恰当经验性抗生素治疗比例显著高于敏感组(81% vs 63%,p<0.001)。
- 多因素logistic回归显示预防性抗生素使用天数是多药耐药呼吸机相关性肺炎的独立预测因素(OR 23.1,95%CI 16.7-28,p<0.001)。
- 多次不恰当经验性抗生素治疗也是多药耐药呼吸机相关性肺炎的独立预测因素(OR 18.1,95%CI 12.2-26.1,p=0.001)。
- 多药耐药组24小时输血量(19 vs 14单位,p=0.009)和下肢简明损伤定级评分(3 vs 1,p<0.001)显著高于敏感组。
- 研究期间多药耐药呼吸机相关性肺炎发生率无显著变化(p=0.633)。
适用人群与场景
- 10年间收治的创伤后发生鲍曼不动杆菌或铜绿假单胞菌呼吸机相关性肺炎的患者,共397例。
诊断标准与关键阈值
- 按病原体敏感性分为敏感组和多药耐药组。
研究设计与关键结果
- 研究类型为10年回顾性队列分析,纳入397例创伤后鲍曼不动杆菌或铜绿假单胞菌呼吸机相关性肺炎患者。
- 鲍曼不动杆菌173例(敏感91例,多药耐药82例),铜绿假单胞菌224例(敏感170例,多药耐药54例)。
- 多药耐药呼吸机相关性肺炎发生率在研究期间无显著变化(p=0.633)。
- 多药耐药组24小时输血量显著高于敏感组(19 vs 14单位,p=0.009),下肢简明损伤定级评分也显著更高(3 vs 1,p<0.001)。
- 多药耐药组多次不恰当经验性抗生素治疗比例显著高于敏感组(81% vs 63%,p<0.001)。
- 多因素logistic回归在校正休克严重程度、损伤严重程度、呼吸机相关性肺炎严重程度和抗生素暴露后,预防性抗生素使用天数(OR 23.1,95%CI 16.7-28,p<0.001)和多次不恰当经验性抗生素治疗(OR 18.1,95%CI 12.2-26.1,p=0.001)是多药耐药的独立预测因素。
证据类型、等级与局限
- 证据类型为回顾性队列研究,证据等级为治疗性Level IV、预后性Level III。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为限制预防性抗生素使用天数是创伤患者发生多药耐药呼吸机相关性肺炎唯一可能可干预的危险因素。
- 作者认为长期暴露于不必要的抗生素仍然是抗生素耐药发生的最强预测因素之一。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Multidrug-resistant (MDR) strains of both Acinetobacter baumannii (AB) and Pseudomonas aeruginosa (PA) as causative ventilator-associated pneumonia (VAP) pathogens are becoming increasingly common. Still, the risk factors associated with this increased resistance have yet to be elucidated. The purpose of this study was to examine the changing sensitivity patterns of these pathogens over time and determine which risk factors predict MDR in trauma patients with VAP.
METHODS: Patients with either AB or PA VAP over 10 years were stratified by pathogen sensitivity (sensitive [SEN] and MDR), age, severity of shock, and injury severity. Prophylactic and empiric antibiotic days, risk factors for severe VAP, and mortality were compared. Multivariable logistic regression was performed to determine which risk factors were independent predictors of MDR.
RESULTS: Three hundred ninety-seven patients were identified with AB or PA VAP. There were 173 episodes of AB (91 SEN and 82 MDR) and 224 episodes of PA (170 SEN and 54 MDR). The incidence of MDR VAP did not change over the study (p = 0.633). Groups were clinically similar with the exception of 24-hour transfusions (14 vs. 19 units, p = 0.009) and extremity Abbreviated Injury Scale (AIS) score (1 vs. 3, p < 0.001), both significantly increased in the MDR group. Antibiotic exposure as well as multiple episodes of inadequate empiric antibiotic therapy (mIEAT) (63% vs. 81%, p < 0.001) were significantly increased in the MDR group. Multivariable logistic regression identified prophylactic antibiotic days (odds ratio, 23.1; 95% confidence interval, 16.7-28, p < 0.001) and mIEAT (odds ratio, 18.1; 95% confidence interval, 12.2-26.1, p = 0.001) as independent predictors of MDR after adjusting for severity of shock, injury severity, severity of VAP, and antibiotic exposure.
CONCLUSION: Prolonged exposure to unnecessary antibiotics remains one of the strongest predictors for the development of antibiotic resistance. Multivariable logistic regression identified prophylactic antibiotic days and mIEAT an independent risk factors for MDR VAP. Thus, limiting prophylactic antibiotic days is the only potentially modifiable risk factor for the development of MDR VAP in trauma patients.
LEVEL OF EVIDENCE: Level IV Therapeutic; level III Prognostic.
参考来源
- Lewis RH, Sharpe JP, Swanson JM, et al. Reinventing the wheel: Impact of prolonged antibiotic exposure on multidrug-resistant ventilator-associated pneumonia in trauma patients. J Trauma Acute Care Surg. 2018. PMID: 29664891. doi:10.1097/TA.0000000000001936
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。